Fei Su

4.7k total citations
123 papers, 2.7k citations indexed

About

Fei Su is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Fei Su has authored 123 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 37 papers in Cancer Research and 20 papers in Oncology. Recurrent topics in Fei Su's work include Cancer-related molecular mechanisms research (24 papers), RNA modifications and cancer (19 papers) and MicroRNA in disease regulation (16 papers). Fei Su is often cited by papers focused on Cancer-related molecular mechanisms research (24 papers), RNA modifications and cancer (19 papers) and MicroRNA in disease regulation (16 papers). Fei Su collaborates with scholars based in China, United States and United Kingdom. Fei Su's co-authors include Robert J. Schneider, Songhua Hu, Ping Xu, Arnold J. Levine, Kathryn Packman, Gideon Bollag, Brian Higgins, David Heimbrook, Kenneth Kolinsky and Hong Yang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Fei Su

116 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fei Su China	26	1.8k	654	633	246	231	123	2.7k
Markus List Germany	25	1.9k 1.0×	553 0.8×	397 0.6×	133 0.5×	350 1.5×	106	3.1k
Ruchir Shah United States	27	2.6k 1.4×	867 1.3×	624 1.0×	275 1.1×	429 1.9×	73	4.1k
Jinglin Xia China	30	1.2k 0.6×	702 1.1×	694 1.1×	391 1.6×	325 1.4×	107	2.8k
Linghua Meng China	30	1.7k 0.9×	274 0.4×	623 1.0×	108 0.4×	228 1.0×	109	2.9k
Sahng Wook Park South Korea	24	1.9k 1.1×	1.1k 1.7×	410 0.6×	396 1.6×	447 1.9×	53	4.4k
Zheng Yang United States	36	1.3k 0.7×	238 0.4×	845 1.3×	230 0.9×	336 1.5×	107	3.5k
Ikuo Horii Japan	23	1.6k 0.9×	352 0.5×	1.1k 1.8×	174 0.7×	194 0.8×	85	3.0k
Hai Huang China	27	1.4k 0.7×	644 1.0×	346 0.5×	196 0.8×	141 0.6×	80	2.2k
Lina Yang China	25	1.0k 0.6×	383 0.6×	533 0.8×	128 0.5×	302 1.3×	113	2.2k
Yuan Liu China	34	1.6k 0.9×	514 0.8×	895 1.4×	163 0.7×	310 1.3×	149	3.3k

Countries citing papers authored by Fei Su

Since Specialization

Citations

This map shows the geographic impact of Fei Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Su more than expected).

Fields of papers citing papers by Fei Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Su. The network helps show where Fei Su may publish in the future.

Co-authorship network of co-authors of Fei Su

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Su. A scholar is included among the top collaborators of Fei Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Su. Fei Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Tao, Ruoqi Wang, Yu-Bin Yang, et al.. (2025). KLF5 facilitates lung adenocarcinoma metastasis by regulating the epithelial-mesenchymal transition pathway through RHPN2. Journal of Translational Medicine. 23(1). 1078–1078.

Yang, Gang, et al.. (2024). HNF1A induces glioblastoma by upregulating EPS8 and activating PI3K/AKT signaling pathway. Biochemical Pharmacology. 223. 116133–116133. 1 indexed citations

Su, Fei, et al.. (2024). CircVDAC3 sequesters microRNA-592 and elevates EIF4E3 expression to inhibit the progression of gastric cancer. Translational Oncology. 45. 101972–101972.

Zhang, Tao, Fei Su, Bofang Wang, et al.. (2024). Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma. Oncogene. 43(16). 1190–1202. 9 indexed citations

Johnson, Amber M., Patrick Kwok‐Shing Ng, Michael Kahle, et al.. (2023). Actionability classification of variants of unknown significance correlates with functional effect. npj Precision Oncology. 7(1). 67–67. 6 indexed citations

Su, Fei, et al.. (2022). Research on Coupling Coordination of China’s New-Type Urbanization and Urban Resilience—Taking Yangtze River Economic Belt as an Example. Sustainability. 15(1). 456–456. 11 indexed citations

Zhang, Tao, Bofang Wang, Baohong Gu, et al.. (2022). Genetic and Molecular Characterization Revealed the Prognosis Efficiency of Histone Acetylation in Pan-Digestive Cancers. Journal of Oncology. 2022. 1–21. 9 indexed citations

Li, Ying, Meng Wu, Lili Zhang, et al.. (2022). Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner. Cell Death Discovery. 8(1). 402–402. 7 indexed citations

Wu, Qingjun, Hexin Li, Lili Zhang, et al.. (2021). Identification of differentially expressed circular RNAs associated with thymoma. Thoracic Cancer. 12(9). 1312–1319. 9 indexed citations

10.

Yu, Tingting, Tao Zhang, Fei Su, et al.. (2021). ELK1 Promotes Epithelial‐Mesenchymal Transition and the Progression of Lung Adenocarcinoma by Upregulating B7‐H3. Oxidative Medicine and Cellular Longevity. 2021(1). 2805576–2805576. 16 indexed citations

11.

Su, Fei, Fenfang Zhou, Tao Zhang, et al.. (2020). Quantitative proteomics identified 3 oxidative phosphorylation genes with clinical prognostic significance in gastric cancer. Journal of Cellular and Molecular Medicine. 24(18). 10842–10854. 17 indexed citations

12.

Liu, Baoquan, et al.. (2019). Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab. Cancer Chemotherapy and Pharmacology. 84(5). 1039–1049. 29 indexed citations

13.

Li, Shang, Yanjun Xu, Zeguo Sun, et al.. (2016). Identification of a lncRNA involved functional module for esophageal cancer subtypes. Molecular BioSystems. 12(11). 3312–3323. 7 indexed citations

14.

Su, Fei, et al.. (2016). Current Situation and Trend of Hazard Risk Perception. 31(3). 151. 1 indexed citations

15.

Li, Bo, et al.. (2015). Measurement of vulnerability in human-sea economic system based on set pair analysis: A case study of Dalian city. Geographical Research. 34(5). 967–976. 10 indexed citations

16.

Shang, Desi, Haixiu Yang, Yanjun Xu, et al.. (2014). A global view of network of lncRNAs and their binding proteins. Molecular BioSystems. 11(2). 656–663. 20 indexed citations

17.

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2011). Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. Cancer Research. 72(3). 779–789. 170 indexed citations

18.

Su, Fei. (2011). Assessment of Sustainability Status and Trend of Shenyang City Based on DPSIR Framework.

19.

Yang, Hong, Brian Higgins, Kenneth Kolinsky, et al.. (2010). RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. Cancer Research. 70(13). 5518–5527. 307 indexed citations

20.

Su, Fei, Hong Yang, Jianping Chen, et al.. (2007). Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents. Molecular Cancer Therapeutics. 6. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact